Bioprocessing, commonly known as biopharmaceutical manufacturing,
falls under bioprocess engineering used in the cultivation of
therapeutic cells. The end products of bioprocessing are high value
products and used to work on specific target. Two types of processes are
used in biopharmaceutical manufacturing: upstream biopharmaceutical
manufacturing and downstream biopharmaceutical manufacturing. The steps
involved in upstream biopharmaceutical manufacturing process are
development of media, cell culture, harvesting of cells, and
fermentation. The biopharmaceutical manufacturing process is carried out
under aseptic condition at constant temperature. The pH levels are
adjusted according to microorganism used and are monitored during the
entire process. The upstream process provides optimum environment
required for the growth of cells. Upstream biopharmaceutical
manufacturing is used for large scale cultivation of proteins, vaccines,
hormones, antibiotics, enzymes, and other therapeutic products. The
products thus obtained from biopharmaceutical manufacturing are used to
treat chronic diseases such as immunogenic disorders, diabetes mellitus,
and other deficiencies related to growth hormones.
The global upstream biopharmaceutical manufacturing process market is
driven by increasing prevalence of chronic. Continuous technological
innovation has led to high yield of biopharmaceutical production, as
technology aims at faster and easier process of production.
Additionally, increase in awareness about application of upstream
process in cell therapy, cell banking, antibody production, drug
discovery, and recombinant proteins accelerate the growth of the
upstream biopharmaceutical manufacturing process market. High cost of
establishing an upstream processing unit and its maintenance acts as a
restraint of the market.
The global upstream biopharmaceutical manufacturing process market can be segmented based on cell type, process type, product type, end-user, and region. In terms of cell type, the global market can be bifurcated into bacterial cell and mammalian cell. Based on process type, the global upstream biopharmaceutical manufacturing process market can be categorized into continuous biopharmaceutical process systems and single-use biopharmaceutical process system. In terms of product type, the global market can be classified into fermenters and bioreactors. Based on end-user, the global upstream biopharmaceutical manufacturing process market can be divided into contract manufacturing organizations (CMOs), contract research organizations (CROs), biopharmaceutical companies, and academic and research institutes.
In terms of region, the global upstream bioprocessing equipment
market can be segmented into North America, Europe, Asia Pacific, Latin
America, and Middle East & Africa. North America dominates the
global upstream bioprocessing equipment market. The U.S. is the major
contributor to the growth of the upstream biopharmaceutical
manufacturing process market in the region, as a lot of research
activities are carried in this field. The U.S. dominates the use of
single use biopharmaceutical manufacturing process systems as compared
to continuous biopharmaceutical manufacturing process system. Europe is
the second largest market due to presence of key players. The market in
Latin America and Middle East & Africa is witnessing sluggish
growth, but are expected to project great potential as increasing
interest of top players to invest in these regions. The upstream
bioprocessing manufacturing process market in Asia Pacific is expected
to grow at a rapid pace due to availability of low cost of processing
units such as CMOs and CROs. In Asia Pacific, mainly Japan contributes
the growth of the market due to contribution of the Japanese
biopharmaceutical and food & beverage industry.
Key players in the global upstream biopharmaceutical manufacturing process market are Merck KGaA, GE Healthcare, Thermo Fisher Scientific, Boehringer Ingelheim Pharma GmbH & Co. KG, BiOZEEN, and Katalyst Bio Engineering, among others.
Report Overview @ https://www.transparencymarketresearch.com/upstream-biopharmaceutical-manufacturing-process-market.html
The global upstream biopharmaceutical manufacturing process market can be segmented based on cell type, process type, product type, end-user, and region. In terms of cell type, the global market can be bifurcated into bacterial cell and mammalian cell. Based on process type, the global upstream biopharmaceutical manufacturing process market can be categorized into continuous biopharmaceutical process systems and single-use biopharmaceutical process system. In terms of product type, the global market can be classified into fermenters and bioreactors. Based on end-user, the global upstream biopharmaceutical manufacturing process market can be divided into contract manufacturing organizations (CMOs), contract research organizations (CROs), biopharmaceutical companies, and academic and research institutes.
Key players in the global upstream biopharmaceutical manufacturing process market are Merck KGaA, GE Healthcare, Thermo Fisher Scientific, Boehringer Ingelheim Pharma GmbH & Co. KG, BiOZEEN, and Katalyst Bio Engineering, among others.
No comments:
Post a Comment